COVID-19 Oral Antivirals Transitioning to Commercial Marketplace
The federal government is transitioning COVID-19 oral antiviral treatments Paxlovid (nirmatrelvir packaged with ritonavir) and Lagevrio (molnupiravir) to the commercial market. To learn about upcoming milestones and timelines, see
Sunsetting the U.S. Government COVID-19 Therapeutics Distribution Program.
See Important Dates
During public health events, health care organizations, large pharmacy chains, states, territories, and federal agencies need to be able to rapidly order, distribute, and account for federally supplied medical countermeasures. Since 2020, these organizations have used HPOP to order medical countermeasures for over 180,000 provider sites nationwide. HHS provided these medical countermeasures to recipients at no cost for distribution within communities in need.
HPOP was originally designed to enable our partners to order, distribute, and track inventory of COVID-19 medical countermeasures, and later adapted for the distribution of mpox vaccine and therapeutics. HPOP has been used to track in-field inventory and administration of medical countermeasures through these responses.
In 2023, H-CORE coordinated the enhancement of HPOP, incorporating feedback from users and lessons learned during responses to the COVID-19 pandemic and the mpox outbreak in the United States.
The enhanced system is ready to be used to order other federally supplied medical countermeasures and other resources needed for future public health response operations as needed. There are over 40,000 users of the HPOP system who have ordered and distributed tens of millions of treatment courses of
COVID-19 therapeutics, nearly one million vials of
JYNNEOS vaccine for the prevention of mpox, and thousands of courses of
TPOXX for the treatment of mpox.
Which products are currently being distributed under HPOP?
Currently, HPOP is being used for the ordering, distribution, and reporting of the JYNNEOS vaccine, and oral TPOXX. Federal entities can continue ordering, distribution, and reporting Paxlovid and federal entities, other than DoD and VA, can continue ordering, distribution, and reporting Lagevrio in HPOP. USG closed ordering for Lagevrio for all jurisdictions, pharmacy, and other partners on November 10, 2023, at 3:00 PM ET and closed ordering for Paxlovid products (standard and reduced dose packaging) for all jurisdiction, pharmacy, and other partners on December 15, 2023, at 3:00 PM ET, see Sunsetting the U.S. Government COVID-19 Therapeutics Distribution Program.
What entities have ordered products using HPOP?
State and territorial jurisdictions, large health care organizations, large pharmacy chains, and federal entities (e.g., Department of Defense, Department of State, Indian Health Service) have served as HPOP partners. HPOP partners can order federally distributed medical countermeasures through HPOP.
HPOP is designed around the concept of a partner managing their own sites. In HPOP, partners may allocate product to sites in their organizations or enable their sites to directly request the product and amount needed for distribution.
A site is the individual care location that receives products (e.g., an individual pharmacy location, a doctor’s office, or a hospital). Sites are managed and onboarded by the partner.
How can HPOP users get help?
If you are having trouble accessing your account or using the HPOP system, please email HPOP.Support@hhs.gov.
